Acasti Pharma to Present at the H.C. Wainwright BioConnect 2022 Conference
January 03 2022 - 8:30AM
Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and
TSX-V: ACST), today announced that Jan D’Alvise, President and CEO
of Acasti, will be presenting at the H.C. Wainwright BioConnect
2022 Conference being held virtually January 10-13, 2022.
Acasti’s presentation will be available
on-demand to registered attendees via the conference platform
beginning Monday, January 10, 2022 at 7:00 AM Eastern Time.
The webcast of the Company’s presentation can be
accessed here: journey.ct.events/view and on the investor relations
section of Acasti’s website at acastipharma.com/en/investors as of
7:00 AM Eastern Time on Monday, January 10, 2022.
About Acasti
Acasti is a specialty pharma company with drug
delivery capability and technologies addressing rare and orphan
diseases. Acasti’s novel drug delivery technologies have the
potential to improve the performance of currently marketed drugs by
achieving faster onset of action, enhanced efficacy, reduced side
effects, and more convenient drug delivery—all which could help to
increase treatment compliance and improve patient outcomes.
Acasti’s three lead clinical assets have each
been granted Orphan Drug Designation by the FDA, which provide the
assets with seven years of marketing exclusivity post-launch in the
United States and protection by over 40 granted and pending
patents. The lead assets target underserved orphan diseases: (i)
GTX-104, an intravenous infusion targeting Subarachnoid Hemorrhage
(SAH), a rare and life-threatening medical emergency in which
bleeding occurs over the surface of the brain in the subarachnoid
space between the brain and skull; (ii) GTX-102, an oral mucosal
spray targeting Ataxia-Telangiectasia (A-T), a progressive,
neurodegenerative genetic disease that primarily impacts children
causing severe disability, for which no treatment currently exists;
and (iii) GTX-101, a topical spray, targeting Postherpetic
Neuralgia (PHN), a persistent and often debilitating neuropathic
pain caused by nerve damage from the varicella zoster virus
(shingles), which may persist for months and even years. For more
information, please visit: https://www.acastipharma.com/en.
Neither NASDAQ, the TSXV nor its Regulation
Services Provider (as that term is defined in the policies of the
TSXV) accepts responsibility for the adequacy or accuracy of this
release.
Acasti Contact:Jan
D’AlviseChief Executive Officer Tel: 450-686-4555Email:
info@acastipharma.com www.acastipharma.com
Investor Contact:Crescendo
Communications, LLC Tel: 212-671-1020Email:
ACST@crescendo-ir.com
Media Contact :Jules AbrahamJQA Partners,
Inc.Tel: 917-885-7378Email: jabraham@jqapartners.com
Acasti Pharma (NASDAQ:ACST)
Historical Stock Chart
From Aug 2024 to Sep 2024
Acasti Pharma (NASDAQ:ACST)
Historical Stock Chart
From Sep 2023 to Sep 2024